The Importance of Co-Testing in Cervical Cancer Screening - Sponsored by Hologic, Inc.
The incidence of cervical cancer incidence is no longer decreasing. A Pap test is used to find cell changes or abnormal cells in the cervix. These abnormal cells may be precancer or cancer, but they may also be other things, too. The HPV test looks for cervical infection by high-risk types of HPV that are more likely to cause pre-cancers and cancers of the cervix. The test can be done by itself or at the same time as the Pap test (with the same swab or a second swab). Pap + HPV co-testing is the most sensitive screening strategy available for detecting cervical cancer and precancer. This session will discuss the improved safety and effectiveness of Pap + HPV co-testing using real-world data that reflects current clinical practice in the United States. Dr. Michael D. Randell will present background information and data, review the latest guidelines, and explore advocacy concerns.
EDUCATIONAL OBJECTIVES
* Review the incidence of cervical cancer
* Discuss the use of Pap + HPV co-testing for detecting cervical cancer & precancer
* Explore concerns unique to correctional settings for use of the co-test
ABOUT THE PRESENTER
Michael D. Randell, M.D., F.A.C.O.G. is an award winning Board Certified Obstetrician and Gynecologist in private practice in Atlanta, Georgia and is also on the medical staff at Emory Saint Joseph's Hospital in the Department of Gynecology. His research interests in managing cancer during pregnancy, the effects of barometric pressure changes on the initiation of labor, and the treatment of atypical Pap smears have led to award winning presentations at scientific meetings. Dr. Randell is regularly invited to speak at national medical conferences and is frequently interviewed by the news media on issues related to women’s health care.
Webinar Fee:
This sponsored webinar is free and includes the powerpoint presentation, the webinar recording and CE credit - 1.0 hours for ACCME, ADA, ANCC, APA and CCHP